The Show-Me Quarter Showed Up: CAS +71%, a Best-Case NCD, and the First Organic Guide Raise of the Year — Upgrading to Outperform

Results vs. Consensus

Q2 FY2026 Scorecard

Year-Over-Year Comparisons

Quarter-Over-Quarter Comparisons

Quality of Beat

Revenue: the cleanest top-line print of the fiscal year. The 5.5% organic result needed no footnote gymnastics — the "Other" revenue and divestiture adjustments were small and symmetric versus the prior year, and FX ($111M) is excluded from the organic calc. The acceleration came from exactly where the thesis needs it: Cardiovascular +9.3% organic with CAS contributing the swing, while the U.S. CRHF business grew 19.9%. The geographic balance also improved — double-digit Japan, mid-single-digit U.S., Western Europe, and China — against Q1's lopsided international skew. The remaining soft spots (MedSurg +1.3%, U.S. MedSurg slightly negative) were guided to and are launch-dependent (Hugo) rather than demand-driven.

Margins: the gross margin inflection is the most analytically significant data point in the print. Q1's bridge showed COGS programs being swamped by the Affera ramp comparison; Q2's bridge shows the regime change management promised: +30bp pricing, +40bp COGS efficiency net of inflation (Affera headwind "now behind us"), −80bp mix (CAS capital + Simplera ramp, both growth-driven), −20bp tariffs, +100bp FX. Strip the FX and the operational engine still covers most of the mix drag. Operating margin of 24.1% fell 20bp YoY only because management chose to spend into the momentum — R&D up 8.9% (230bp above revenue growth) and a deliberate S&M step-up for the PFA/Ardian launches, with G&A held to less than half revenue growth. This is margin investment with a stated payback, not slippage.

EPS: $1.36 versus the $1.31 guide midpoint, with the CFO immediately decomposing the beat: ~$0.035 tax timing (reverses in Q4), remainder operational flow-through. The transparency cuts both ways — it means the underlying beat was ~$0.015, and it means the FY26 raise to $5.62–$5.66 (floor up $0.02, ceiling unchanged) is the honest arithmetic rather than a stingy one. The 8% YoY EPS growth against 5.5% organic revenue growth shows the leverage algorithm beginning to function even while absorbing $185M of annualized tariffs and a heavy investment quarter.

Segment Performance

Portfolio Revenue Mix — Q2 FY2026

Cardiovascular — A Decade-Best Quarter With a Self-Funding Flywheel

Cardiovascular's 9.3% organic growth is the segment's best ex-pandemic print in over ten years, and the composition validates the August thesis. CAS grew 71% with U.S. PFA up over 300%; PFA is now 75% of CAS revenue, absorbing a 40% decline in legacy cryoablation (90% of remaining cryo revenue is outside the U.S., so the cannibalization is nearly complete domestically). Cardiac Rhythm Management grew 5% — 14.3% organic for the broader CRHF division — with Micra +18% and AURORA EV-ICD up nearly 80%. Structural Heart grew 7% on Evolut, still harvesting share from a competitor's international exit. Coronary & Peripheral Vascular at +0.8% remains the laggard pending the NeuroGuard carotid stent and Liberant thrombectomy launches.

"In the vast majority of instances, when a new Affera system goes into a lab, we take the majority of the AF procedure share in that lab… we've doubled our installed base of Affera mapping systems during the quarter. And given the economics of this business with capital and consumables, our mapping system sales are a strong leading indicator of future revenue growth and margin expansion." — Geoff Martha, Chairman & CEO

Assessment: the doubled Affera installed base is the most forward-loaded disclosure in the print. Mapping-system capital books at lower margin today and converts to high-margin catheter annuity for years — meaning Q2's mix headwind is literally the prepayment for FY27's margin tailwind. With management explicitly guiding CAS growth higher again in Q3 and the $1B increment now framed as arriving "shortly, probably the beginning of fiscal '27," the franchise is executing ahead of every commitment made in August.

Neuroscience — The Recovery Arrived on Schedule

Neuroscience returned to 4% growth as management promised in August. Cranial & Spinal Technologies grew 5% (Core Spine +8% globally and in the U.S.), with the AiBLE ecosystem — AI preoperative planning, robotics, navigation, imaging, powered instruments — continuing to pull through Core Spine hardware share. Neuromodulation grew 7.3% organic with both Pain Stim and Brain Modulation high-single-digit on the Inceptiv and BrainSense closed-loop rollouts. Specialty Therapies improved from −2.7% to flat, as guided, on ENT and Neurovascular improvement — with the China VBP anniversary in January and the Altaviva launch set to carry the division to growth in Q3.

Assessment: a segment executing to plan, quarter by quarter. The Altaviva approval (see Key Topics) converts Pelvic Health from a Q1 drag into a multi-year growth driver, and the Neurovascular comps clear in January. We expect Neuroscience to be a 5%+ grower by Q4 — not spectacular, but the point of the portfolio: steady mid-single-digit base businesses funding the high-growth drivers.

Medical Surgical — Still the Show-Me Segment, but Endoscopy Shines

MedSurg grew 1.3% organic, with Surgical at +1% on emerging-market tender timing plus the familiar bariatric and robotics-shift pressures. The bright spot was Endoscopy at +8%, driven by double-digit growth in esophageal products and GI Genius, the AI polyp-detection platform. The Hugo file advanced materially: the Enable hernia study met its safety and effectiveness endpoints, the Embrace gynecology U.S. pivotal began enrollment, and management still expects FDA approval of the urology indication — and the start of the U.S. launch — in the back half of the fiscal year.

Assessment: MedSurg remains the portfolio's lowest-growth pillar and the only segment where the FY26 inflection case rests entirely on a product that hasn't been approved yet. The hernia data matter more than they appear: hernia repair is the volume workhorse of general surgery robotics, and a U.S. label expansion path (urology → hernia → gyn) is how Hugo becomes commercially relevant rather than symbolically present. We keep expectations low into the approval and view any FY26 Hugo revenue as option value.

Diabetes — The Order Book Says the Air Pocket Is Ending

Diabetes grew 7.1% organic with international +11% and the U.S. slightly negative (−0.8%) — but the U.S. softness now has a countable resolution: customers paused orders awaiting the new sensors, and Medtronic banked more than 35,000 U.S. orders and preorders for Simplera Sync and the Abbott-partnered Instinct sensor, with roughly 25% from new pump users or existing pump users new to Medtronic CGM, plus over 9,000 new U.S. prescribers. Instinct began shipping in late November; Simplera Sync rolls out more broadly to U.S. consumers later this fiscal year. The pipeline stacked further wins: FDA approval of 780G for type 2 diabetes (September), clearance of SmartGuard-Instinct integration, U.S. pivotal approval for the third-generation Vivera algorithm, and the MiniMed Flex pump submission on track.

"We accumulated more than 35,000 U.S. customer orders for Simplera Sync and preorders for Instinct. Around 25% of these orders are from new pump users or our Medtronic pump users who were not using our CGM… For those of you who follow this space, you know how big a deal these numbers are." — Thierry Pieton, CFO

Assessment: the order data converts August's "trust the timing" story into a measurable backlog. A 25% new-user share means the sensor cycle is expanding the installed base, not just upgrading it — the difference between a replacement cycle and a growth cycle. With the separation now targeted for completion by end of calendar 2026, MiniMed is being dressed for its IPO in the best operational shape of its history; expect the U.S. growth inflection to be visible by Q4.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: the posture shifted from August's "trust the calendar" to November's "read the scoreboard" — nearly every claim on the call was anchored to a delivered number, a signed payer, a met endpoint, or a banked order. The confidence was specific rather than rhetorical, and the willingness to pre-announce bad optics (Q3 margins down ~200bp on tariff concentration, the tax-timing reversal) signals a management team managing credibility, not just quarters. The one place the tone outran the evidence was robotics, where enthusiasm about Hugo's differentiation still substitutes for any disclosed commercial metric.

1. CAS at +71%: The Promise Was Kept, Then Raised Again

August's commitment was that Q2 CAS growth would exceed Q1's ~50%. It came in at 71%, with U.S. PFA up over 300%, and management immediately re-upped: Q3 will be higher still. The mechanics behind the number are the story — the installed base of Affera mapping systems doubled in a single quarter, supply is explicitly "not holding us back," and mapper hiring is "staying ahead" of demand. The EP ablation market itself was revised upward in management's framing, from $11B growing 25%+ to over $12B growing mid-twenties.

"PFA will continue to go off the 71%. It'll accelerate into Q3 and beyond." — Thierry Pieton, CFO

Assessment: three quarters into the Affera scale-up, every operational claim has been met or exceeded on schedule. The competitive claim worth monitoring is the share dynamic inside accounts — "when a new Affera system goes into a lab, we take the majority of the AF procedure share in that lab." If that holds as the installed base compounds, Medtronic's low-double-digit share of a $12B market has a long runway; it also means the fight with the incumbent PFA leader will increasingly be account-by-account capital warfare, which favors the company with the broader hospital relationship.

2. The Final NCD: Better Than the Proposal, and the Moat Has a Paper Trail

The October 8 catalyst we flagged in August resolved at the favorable tail of outcomes. The final NCD broadened patient access versus the proposal: in-person visit requirements reduced, the kidney-function exclusion removed, the medication-adherence time requirement halved, and patient quality of life elevated as an explicit consideration — with physician-discretion language creating practical pathways to therapy. Medtronic is currently the only company meeting the full NCD criteria with an approved continued-evidence-development plan. Commercial payers followed faster than management expected: HCSC and several Blue Cross Blue Shield plans covering ~30 million lives signed during the quarter.

"This isn't a question of if or even how big. A question of how fast… we're measuring that speed of adoption in quarters, not years." — Geoff Martha, Chairman & CEO

Assessment: the regulatory risk we refused to underwrite in August is now substantially retired. What remains is a commercial execution question with unusually good scaffolding: an exclusive coverage position (the CED-plan requirement is a de facto moat against the ultrasound competitors), three-year durability data (18.5-point systolic reduction at OnMed), and society guidelines on two continents. Management deliberately kept "not much Simplicity revenue" in the back-half guide — the right way to handle a launch whose slope is genuinely unknown. Every dollar of Ardian revenue in H2 is upside to the raised guide.

3. Altaviva: The Third Growth Driver Launches Into an Oversubscribed Market

The tibial neurostimulation device for urge urinary incontinence — FDA-approved during the quarter as Altaviva — launched with physician training programs oversubscribed, capacity being expanded, and early consumer media driving search activity. The product profile is differentiated against sacral nerve modulation on convenience: implanted above the fascia near the ankle without sedation, therapy active the same day, recharging once or twice a year on a 15-year battery. The addressable population is 16 million U.S. patients with urge incontinence inside a 46-million overactive-bladder pool. Management expects it to take share from Botox-based regimens while remaining incremental to the sacral business.

Assessment: Altaviva is the quietest of the three launch drivers and may be the most underwritten-for-free. Pelvic Health was a drag in Q1 (commercial reorg) and flat in Q2; it now has a first-mover implantable in a market where the patient-experience gap versus alternatives (weeks-to-months versus same-day therapy) is unusually wide. The Q1 reorg reads, in hindsight, as deliberate runway-clearing. We model Pelvic Health returning to growth in Q3 and becoming a visible contributor by FY27.

4. The Gross Margin Regime Change: Operational +70bp Against the Mix Tide

Q2's bridge confirms the structural claim management made in August: pricing +30bp (second consecutive quarter), COGS efficiency +40bp net of inflation with the Affera ramp comparison now behind, mix −80bp (CAS capital and Simplera, both growth-driven and both expected to turn), tariffs −20bp, FX +100bp. Management quantified the forward arc: 70–80bp of recurring annual operational gross margin improvement from pricing plus cost-out, with the mix headwind shrinking through FY27 as Diabetes deconsolidates in H2 CY26 and CAS shifts from capital placements to catheter pull-through.

Assessment: this is the quarter the margin algebra started working. The 70–80bp operational engine is the number that compounds; mix is the number that mean-reverts. If both behave as described, FY27 gross margin expands meaningfully even before tariff mitigation — which is the foundation under the high-single-digit FY27 EPS commitment. The 'watch' flag we raised in August (GM still declining by Q4 would threaten the FY27 story) is now resolving in the right direction two quarters early.

5. Spending the Beat: The Growth-Mindset Trade

Management saw the revenue and tax upside forming early in the quarter and chose to spend a portion of it: R&D up 8.9% (230bp above revenue growth, en route to a stated ~10%-of-revenue target over time), and a deliberate sales-and-marketing step-up for mapper hiring, Ardian market development, and direct-to-consumer capability for Simplicity. SG&A still leveraged at the G&A line (growth under half the revenue rate), and management committed to SG&A leverage in H2.

"We just made a decision to go invest in the places that are gonna drive the growth going forward… we took the opportunity that we were gonna see upside on revenue and a little bit on the tax line, just to lean into the investment to make sure we fully capture the opportunities that are ahead of us." — Thierry Pieton, CFO

Assessment: this is the right trade and the honest disclosure of it matters. A company with three simultaneous category launches underspending on commercial infrastructure would be managing the quarter at the expense of the cycle. The discipline test comes in H2: management has now pre-committed to SG&A leverage while sustaining the launch investments — both can be true only if revenue accelerates as guided. The Q4 print will adjudicate.

6. The Q3 Margin Trough, Pre-Announced

Management explicitly guided Q3 margins down approximately 200 basis points, driven by the concentration of half the year's tariff impact ($90–95M of $185M) in the quarter, continued CAS/Diabetes mix acceleration, and seasonally light COGS-program savings through the holidays — with Q4 margins then increasing year-over-year with "strong sequential improvement."

Assessment: telegraphing the trough is good investor relations and good expectation-setting; it also creates a known optical risk. The Q3 print (February) will show 5.5% organic growth with compressed margins and an EPS guide of $1.32–$1.34 that embeds the tax-timing reversal — a quarter that will look mediocre in a headline scan while being entirely on-plan. Position accordingly: weakness on the Q3 print that traces to these pre-announced factors is noise, not signal.

7. The Guide Raise Arithmetic: Top Line Up 50bp, EPS Floor Up $0.02

The FY26 organic guide moved from ~5.0% to ~5.5% — the first organic raise of the year — with Q3 at ~5.5% and Q4 explicitly "even stronger." The EPS range narrowed upward to $5.62–$5.66. The H1 run rate of 5.2% organic means the full-year 5.5% target embeds H2 at approximately 5.8–6.0% — the acceleration is now in the numbers, not just the narrative.

Assessment: a 50bp organic raise from a company that held the same number through two prior quarters is a meaningful signal about order books and launch visibility. The modest EPS raise reflects the tax-timing honesty and the investment decision, not caution about the top line. The implied H2 exit rate near 6% becomes the new baseline for our FY27 model — and management's "we don't wanna slow down from there" comment in Q&A extends the ambition past the fiscal year.

8. Hugo's U.S. Entry: The Data Stack Builds, the Clock Runs

The Enable hernia repair study met its safety and effectiveness endpoints, the Embrace gynecology U.S. pivotal began, and the FDA's urology decision — the U.S. market-entry gate — is still expected in the back half of the fiscal year. The differentiation argument is now framed around modularity, the open console, LigaSure RAS instrumentation, ICG imaging, and the Touch Surgery digital ecosystem operating in 30+ countries.

Assessment: the indication-expansion sequencing (urology → hernia → gyn) is the right commercial architecture — urology gets the approval, hernia gets the volume. But Medtronic still discloses no robot revenue, no placement counts, and no procedure economics, several years into the international launch. We continue to assign Hugo option value only, while noting the launch lands into a U.S. market where the incumbent's installed base is enormous but the unserved mid-market hospital tier is real.

9. Capital Allocation: Tuck-In M&A With a Cardiology Accent

Management confirmed active tuck-in M&A prioritization in higher-growth segments — "a lot of that is in cardiology, some in neuroscience" — explicitly modeled on the Affera profile: at or near market, where Medtronic's commercial infrastructure multiplies the asset. The ventures arm holds stakes in 50+ companies as a pipeline-feeding mechanism, and the portfolio review "at every level" continues under the new Growth Committee with separation execution (MiniMed by end of CY26) as proof-of-work.

Assessment: Affera is the best capital deployment in recent company history, so using it as the M&A template is rational. The discipline question — whether the Growth Committee accelerates good deals or merely blesses more deals — remains open until we see the first transaction. The WAMGR framing ("growing above our WAMGR while raising the WAMGR") is the right scoreboard and conveniently auditable.

Guidance & Outlook

The CFO's framing connected the raise to first-half outperformance and visibility into the acceleration, while the CEO's commentary repeatedly attached the word "momentum" to specific mechanisms — the doubled mapper base, the payer wins, the banked sensor orders. The structural disclosure embedded in the guidance discussion deserves emphasis: 70–80bp of recurring operational gross margin improvement (pricing + COGS programs), business mix turning from headwind to neutral-then-positive through FY27, SG&A leverage resuming in H2, and R&D climbing toward 10% of revenue — that is a complete, internally consistent P&L algorithm, articulated for the first time in this cycle.

Implied Q-over-Q ramp: H1 organic growth of 5.2% against a full-year ~5.5% target implies H2 at ~5.8–6.0%, with Q4 above Q3's ~5.5%. The exit rate approaching 6% — with minimal Simplicity contribution assumed — is the number that re-rates the stock if delivered.

Street at: consensus EPS (~$1.31 for Q2) sat below the delivered $1.36; the full-year Street number now converges on the $5.64 midpoint. The more important consensus gap is FY27, where high-single-digit EPS growth remains above what most models embed for a company with Medtronic's ten-year track record.

Guidance style: the pattern is now established — precise organic guides hit or exceeded, EPS guides beaten modestly with the beats decomposed honestly, and bad optics (Q3 margins) pre-announced. This is a guidance regime built to rebuild credibility, and through two quarters it is working.

Analyst Q&A Highlights

How Commercial Payers Are Treating Symplicity Relative to the NCD

The first question drilled into the texture of the commercial-payer wins: are payers importing the NCD's breadth, or attaching restrictions? Management characterized the Medicare NCD as broader than anticipated — including physician- and patient-discretion language around medication tolerance — and identified one systematic difference in commercial policies: a heavier emphasis on documented medication history before approval.

Q: "Diving into any individual payer, how are those reflective relative to the NCD? Like, are there restrictions being put on? What is the sort of tone of the conversation and how are the payers looking to introduce this within their patient pool?"
— Patrick Wood, Morgan Stanley

A: "The commercial payers… are coming online faster than I believe we anticipated. They're getting a lot of push from patients as well… the Medicare NCD is broad. And it's better than we anticipated… [In] the commercial payers… the one difference that I know of is around the medications. More of an emphasis on being on a few medications for a while."
— Geoff Martha, Chairman & CEO

Assessment: patient pull is showing up in payer behavior — an unusual dynamic for a device procedure and a leading indicator of consumer-driven adoption. The medication-history requirement in commercial policies is a modest friction, not a gate. The coverage stack is assembling faster than any reasonable August model assumed.

Decomposing the Implied ~6% Second-Half Guide

The most model-relevant exchange asked management to split the H2 acceleration between the pipeline and the base business, and to address whether margin flow-through improves with the revenue upside. The answers were unusually complete: PFA carries most of the near-term incremental growth among the new drivers; Simplicity and Altaviva "start to tick up" in H2 and ramp in following quarters; Hugo contributes little before approval; and the base business adds Diabetes reacceleration, sustained Neuromodulation/CST strength, and Neurovascular/Peripheral Vascular improvement on comps and new products.

Q: "The implied second half guide around 6%. And I kind of think about it two buckets, the pipeline and then kind of the base business… And then on the margins in the second half… revenue upside leads to more margin upside in the second half?"
— Travis Steed, BofA Securities

A: "In the back half, the contribution will be more from PFA in that category… On Simplicity, I'd say we're gonna see it start to tick up in the back half of the year. And then ramp in the quarters following that… And then you've got… the base business is a big contributor. PFA is a big contributor. Then you're gonna start to see Simplicity, Altaviva, and a little bit of Hugo."
— Geoff Martha, Chairman & CEO

Assessment: the H2 bridge does not require heroics from the unproven launches — PFA momentum plus Diabetes order conversion plus comp-lapping covers most of the arithmetic, with Simplicity/Altaviva as kickers. That is the right way to build a guide and the main reason we treat the 5.5% as a floor rather than a stretch.

Mapper Capacity, Supply, and Whether the $2B CAS Run Rate Holds

Asked whether mapper staffing and catheter supply can support the doubling of CAS revenue, management was unequivocal: supply "is not holding us back," mapper hiring is "staying ahead" (framed as a company-wide HR effort), and customer demand is running ahead of installed capacity with accounts requesting additional Affera systems for more labs.

Q: "Do you feel like we have enough mappers now? And is supply in a place enough where you can hit the $2 billion?… Then on tibial… could tibial be a billion-dollar product for you guys down the road?"
— Vijay Kumar, Evercore ISI

A: "Supply is in a good spot… the mapper hiring is going well… but I wish the buffer [were] a little bit more because the growth is tremendous… [On tibial:] when they're presented with options — sacral nerve, tibial, Botox — they tend to choose the tibial. So we do think it will take share from Botox… this is gonna make that pelvic health business a growth driver for the company."
— Geoff Martha, Chairman & CEO

Assessment: "I wish the buffer were a little bit more" is the candid version of a high-class problem — demand outrunning even an on-plan capacity ramp. The tibial answer confirmed the share-from-Botox thesis and the incrementality to sacral, which together underpin a credible path to Pelvic Health as a named growth driver.

Where the Investment Dollars Go, and the FY27 Leverage Path

A two-part exchange on the reinvestment program produced the call's most complete articulation of the P&L algorithm: investment flows to the four growth drivers plus technology leadership in core franchises (next-gen Micra, AiBLE); the gross margin engine generates 70–80bp annually from pricing and cost-out; mix turns favorable through FY27 as Diabetes deconsolidates and CAS shifts to catheters; SG&A leverages from H2 onward; and the sum supports high-single-digit FY27 EPS growth.

Q: "How are you thinking about where those dollars are going? How soon should we be thinking about that? And just help us think about the cadence and the ability to still grow operating margin in the face of higher investment."
— Robbie Marcus, JPMorgan

A: "We're generating between those two lines 70 to 80 basis points of gross margin improvement… that negative mix [will] start getting better towards '27… in the second half of '27, diabetes will be deconsolidated, and then on the CAS side, we'll start seeing the shift between the capital equipment and the catheters, which will make that an accretive business as opposed to being dilutive… we're confident… we'll have a leveraged P&L on the operating profit line in 2027."
— Thierry Pieton, CFO

Assessment: this is the algorithm investors have asked Medtronic for, with mechanisms attached to each component. The load-bearing assumption is the mix reversal timing; the CAS capital-to-catheter shift is observable quarterly and will confirm or refute the schedule well before FY27 guidance is set.

The Ardian Ramp: Faster Than the Watchman Analogy

Pressed to defend a previously-floated benchmark — $400M of U.S. renal denervation revenue by roughly year three of launch — and to address the isolated-systolic-hypertension exclusion in the final NCD, management reaffirmed the ambition emphatically and brought the chief medical officer on to quantify the ISH carve-out at under 10% of the addressable population.

Q: "I asked [whether] US Ardian sales could replicate the US Watchman ramp, which is about $400 million in year five, and I believe you said you'd be disappointed if your US Ardian sales didn't achieve $400 million by, I believe, year three… do you still believe you can achieve $400 million US sales by around fiscal 2028?"
— Larry Biegelsen, Wells Fargo Securities

A: "Yes. I would be disappointed if we're at year five at $400 million. We think it would go faster than that. And this final NCD won't hold us back… If you go back five years, and you asked us if we thought we would get this type of NCD, we'd say that's the best-case scenario."
— Geoff Martha, Chairman & CEO

Assessment: management is allowing a ~$400M-by-FY28 U.S. revenue marker to stand — on a business with a current run rate an order of magnitude smaller. That is either the most consequential under-modeled number in large-cap medtech or a future credibility problem; the CFO's separate framing (11% population share ≡ ~$3B revenue) brackets the long-run prize. The next two quarters of procedure ramp data will begin to price it.

Toward a New Growth Algorithm — and Pruning Beyond Diabetes

A two-part question asked whether Medtronic is migrating toward structurally higher top-line growth, and whether portfolio pruning continues past the MiniMed separation. The CFO walked the arithmetic — 5.2% H1, 5.5% Q3, Q4 higher, "we don't wanna slow down from there" — while the CEO confirmed the portfolio review is continuous and committee-supervised, without naming candidates.

Q: "As you think about growth, should we think about Medtronic moving towards that high single digit on the top line? And then on portfolio management… should we expect portfolio pruning beyond diabetes?"
— Shagun Singh, RBC Capital Markets

A: "We were at 5.2 at the end of the first half. We're guiding at 5.5 in the third quarter. You can do the math for what fourth quarter looks like. And we don't wanna slow down from there… 11% of market share [in hypertension] is almost $3 billion of revenue for us… those come in increment to the rest of the business, and the rest of the business is not standing still."
— Thierry Pieton, CFO

Assessment: management declined to say "high single digit top line" while constructing a staircase that points there — the disciplined version of ambition. On pruning, the non-denial confirms the Growth Committee is evaluating further moves; we'd nominate the slowest-growth MedSurg subsegments as logical candidates and view any such announcement as a positive catalyst.

The ASC Migration and TAVR's Telegraphed Q3 Wobble

On the shift of AF ablation toward ambulatory surgery centers, management framed ASCs as incremental market expansion with dedicated market-development hiring underway. On TAVR, management volunteered a Q3 deceleration on order phasing — with a Q4 recovery expected — while clarifying emphatically that the deceleration comment applied to TAVR only, not PFA.

Q: "As AF ablation is moving to the ASC setting, can you talk about how you are positioned in the ASC in terms of mappers and the Affera placements? And on TAVR, can you talk about what you saw [in] The U.S., Europe and Japan?"
— Pito Chickering, Deutsche Bank

A: "Over time, we do see [ASCs] as an incremental opportunity for market expansion… [On TAVR:] a little bit of a deceleration in Q3, but then it'll pop back up in Q4… And just for clarity, PFA will continue to go off the 71%. It'll accelerate into Q3 and beyond."
— Geoff Martha, Chairman & CEO; Thierry Pieton, CFO

Assessment: the TAVR phasing comment is a useful pre-disclosure — expect a soft structural heart print in February and don't over-read it. The ASC positioning work matters more than it sounds: site-of-care migration is where ablation economics get rewritten, and early mapper/capital presence in ASCs protects the share-capture model as volume shifts.

What They're NOT Saying

1. Simplicity is still a rounding error in reported revenue: the entire NCD/payer narrative is forward-looking — management deliberately embedded "not much" RDN revenue in H2 guidance, and no current procedure volumes or revenue run rate were disclosed on the call. The story is real; the revenue is next year's.
2. The FY26 EPS raise is $0.01 at the midpoint: a 50bp organic raise converted into almost no EPS raise once the tax-timing reversal and the discretionary spend-up are netted. Fine this year; but FY27's high-single-digit EPS commitment now carries the full burden of proving the leverage algorithm.
3. No Elliott or governance update: after headlining the August call, the activist partnership got zero airtime — no committee progress report, no Investor Day date specifics beyond "next year." Either the work is proceeding quietly (benign) or the urgency has faded with the stock at highs (worth watching).
4. Hugo still has no disclosed numbers: "30+ countries" and digital-ecosystem adoption claims continue to substitute for revenue, placements, or utilization metrics. The U.S. approval will force quantification; until then the robotics narrative is entirely qualitative.
5. U.S. weakness outside CRHF persists: U.S. Structural Heart +0.4%, U.S. MedSurg −0.1%, U.S. Diabetes −0.8%, U.S. Specialty Therapies −2.2%. The U.S. acceleration is currently a one-engine story (CRHF +19.9%, powered by CAS). The H2 launches are supposed to broaden it; the breadth is not yet visible.
6. Cryoablation's collapse is being absorbed silently: cryo declined 40% and PFA's growth is partly cannibalization of Medtronic's own legacy franchise. The net CAS number (+71%) is what matters and it is spectacular — but the gross PFA momentum overstates net new franchise value by the size of the cryo runoff.
7. The MiniMed IPO window and valuation remain unframed: "complete by end of calendar 2026" with a two-step IPO-then-split is the entire public schedule. No bankers, no exchange, no valuation context, no use-of-proceeds — for a transaction that reshapes the company's growth and margin profile within five quarters.

Market Reaction

• Pre-print setup: MDT closed Monday November 17 at $96.28, up ~21% year-to-date and ~7% above its pre-August-print level, having fully recovered the August earnings-day selloff and printed new 52-week highs in early November. Expectations were elevated: the NCD had already landed publicly in October, putting the burden on the quarter to validate the run.
• Day-of session: the stock gapped up ~3.8% at the open to $99.97 and extended through the session to close at $100.80, +4.7% on 22.0M shares (~3x average volume) — crossing the $100 threshold for the first time in years and holding it into the close.

The contrast with August is instructive: in August, good headlines met a market that wanted evidence and sold the print; in November, the evidence arrived — accelerating organic growth, a kept CAS promise, payer adoption running ahead of plan, an organic guide raise — and the market paid for it through a psychologically loaded round number. A +4.7% move on a quarter where the EPS beat was largely tax timing tells you what the market is actually pricing: the top-line acceleration and the de-risked Ardian launch, not the quarterly EPS arithmetic.

The setup from here carries a known wrinkle: management has pre-announced that Q3 (February print) will be the year's margin trough with heavy tariff concentration. A stock that just broke out above $100 on acceleration enthusiasm meeting a deliberately soft-optics quarter is a recipe for post-print volatility that has nothing to do with the thesis — a buying opportunity if the organic number holds ~5.5%.

Street Perspective

Debate: Is the PFA Share Grab Durable or a Phase?

Bull view: the Affera account-capture dynamic (majority procedure share wherever a system lands), a doubled installed base feeding multi-year catheter annuities, and the Sphere-360 single-shot pipeline mean Medtronic's EP share gains compound from low-double-digits in a $12B market growing mid-twenties — the single largest organic growth vector in large-cap medtech.

Bear view: the incumbent PFA leader retains the larger installed base and the field-force advantage; +300% U.S. PFA growth off a small base is the easy phase, and as penetration matures the fight shifts to durability data and workflow lock-in where the leader's scale tells; meanwhile 40% cryo declines show how fast EP franchises erode when technology turns.

Our take: both can be true — this is becoming a two-horse market and the market is growing fast enough to feed both. The account-level capital dynamic favors continued Medtronic share gains for at least 4–6 more quarters (the installed-base doubling hasn't yet converted to full catheter pull-through). The durability claims physicians are reportedly making about Affera are the variable that could extend the run beyond that window.

Debate: How Fast Is the Ardian Ramp, Really?

Bull view: best-case NCD, commercial payers covering 30M lives within weeks, exclusive CED-plan qualification, three-year durability data, society guidelines, patient pull, and a CEO standing behind $400M U.S. revenue by roughly year three — the fastest de-novo market build since transcatheter valves.

Bear view: de-novo procedure markets always ramp slower than device makers project — referral pathways from primary care to interventional cardiology don't exist yet, site-of-service economics are unproven, and the history of renal denervation itself (a decade of false starts) argues for humility; the ISH exclusion and commercial-payer medication requirements add quiet friction.

Our take: we underwrite the slow-bull case: the coverage architecture is too favorable and the patient pool too large for failure, but we model meaningful revenue contribution beginning FY27, treating any H2 FY26 contribution as upside — exactly how management built the guide. The February and June prints will give the first real procedure-volume reads; the $400M-by-FY28 marker is the number to track management against.

Debate: Does the Spend-Up Threaten the FY27 EPS Commitment?

Bull view: the company is funding three simultaneous category launches from revenue upside while still delivering 8% EPS growth, the gross margin engine (70–80bp operational/year) is now visible, and the mix headwind mechanically reverses as Diabetes deconsolidates and CAS catheters scale — high-single-digit FY27 EPS is conservative if revenue exits FY26 near 6%.

Bear view: R&D is marching toward 10% of revenue, S&M is expanding into launches whose revenue is back-loaded, tariffs carry into FY27, and the tax rate normalizes in Q4 — the spending is permanent, the offsets are projected, and Medtronic's decade-long history is precisely one of investment phases that never converted to leverage.

Our take: the bear argument is really an argument about management credibility, and the past two quarters have been the strongest credibility-building stretch in years — commitments made specific, then met, then raised. We side with the bull case while respecting the checkpoint structure: SG&A leverage must be visible in H2 prints, and the CAS capital-to-catheter mix shift must show up in gross margin by mid-FY27.

Model Update Needed

Valuation impact: at $100.80, MDT trades at ~17.9x the FY26 guide midpoint ($5.64) with a ~2.8% dividend yield. High-single-digit FY27 EPS growth implies ~$6.05–$6.15, putting the stock at ~16.5x forward-plus-one — still a wide discount to large-cap medtech growth peers trading in the mid-20s-to-30s, despite an organic growth rate now converging toward theirs. Our framework moves to $112–120 on FY27 earnings power at a modestly re-rated 18.5–19.5x — achievable without heroic multiple assumptions if the H2 exit rate near 6% organic is delivered. The upgrade is rate-of-change driven: the evidence now runs ahead of the price.

Thesis Scorecard Post-Earnings

Overall: thesis decisively strengthened. The August framework set four tests for an upgrade; all four resolved bullishly within one quarter — U.S. growth improved, CAS exceeded its commitment, the NCD landed at the favorable tail, and the sensor launch produced a countable order book.

Action: upgrade to Outperform from Hold. Watch items for Q3 (February 17): organic growth holding ~5.5% through the pre-announced margin trough, first Symplicity procedure-ramp commentary, Hugo's FDA decision timing, and CAS sustaining its growth rate against stiffening comps. Treat tariff-driven Q3 margin optics as noise if the top line delivers; a post-print dip on telegraphed margin compression would improve the entry, not the thesis.